ENANTA PHARMACEUTICALS, INC Deferred Tax Expense from Stock Options Exercised
ENANTA PHARMACEUTICALS, INC (ENTA) reported Deferred Tax Expense from Stock Options Exercised of -$105.00 thousand for the 9-month period ending 2014-06-30, per its 10-Q filed 2014-08-12.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:DeferredTaxExpenseFromStockOptionsExercised · last filed 2014-08-12
- 2014-06-30: Deferred Tax Expense from Stock Options Exercised 9 month -$105.00K.
| Period end | Deferred Tax Expense from Stock Options Exercised 9 month |
|---|---|
| 2014-06-30 | -$105.00K 10-Q · filed 2014-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |